TiGenix: TiGenix reports its full year 2014 results

Posted: March 18, 2015 at 2:56 am

Regulated information PRESS RELEASE

TiGenix reports its full year 2014 results

Leuven, Belgium - 17 March, 2015 - TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, reported its results for 2014 today.

Business highlights

Strategic refocusing successfully completed

All resources focused on advancing the allogeneic expanded adipose-derived stem cell (eASCs) product pipeline. ChondroCelect marketing and distribution rights licensed to Sobi and Dutch manufacturing facility sold to PharmaCell

Management team strengthened with the appointment of Chief Medical Officer and VP Medical Affairs & New Product Commercialisation

Patient recruitment of Cx601 European Phase III study completed

Cx601 development for the United States progressed according to plan

Phase III trial design submitted to the Food and Drug Administration (FDA) for a Special Protocol Assessment (SPA)

Originally posted here:
TiGenix: TiGenix reports its full year 2014 results

Related Post